GENERAL COMMENTS
The authors present a metaanalysis on the use of positron emission tomography (PET) with F-18-FDG for staging of rhabdomyosarcoma (RMS) in children and adolescents. The metaanalysis is competently carried out, however the literature on the subject is so scarce that the inclusion criteria for studies had to be changed from 20 patients or more to 10 or more. Because of the high quality of the paper with a very exhaustive literature search I recommend publication in BMJ after a minor revision (see my comments to the authors for details).
I have a few minor comments:
The authours put the reference marks behind the punctuation marks; when reference marks are in round or square brackets they are supposed to appear in front of the punctuation marks. years, the term "PET process" is not familiar to me. You apparently mean the entire workflow from FDG-production, patient preparation, injection of tracer, incubation time, imaging protocol and acquisition, reading and semi-quantification using Standardized Uptake Value (SUV). Your wording has to be more precise here. You might want to write: "We also assessed in how far accepted guidelines for semiquantification using Standardized Uptake Value (SUV) were followed." Then it is clearer what you mean. P. 5. Line 1 ff: you should add a reference mark for each of the three studies, not just the last. P. 6: I prefer the older and more established term fluorodeoxyglucose rather than fludeoxyglucose (even though the latter is now the main heading in Wikipedia). The legend on p. 18 should show the line color AND the symbol. Figure 1 is rather messy due to overplotting. It is difficult for me to give you a good recommendation how you can tidy up the diagram. You might want to add some jitter -see http://stackoverflow.com/questions/3584329/how-to-avoidoverplotting-for-points-using-base-graph for an example.
VERSION 1 -AUTHOR RESPONSE
Response to reviewers comments: Reviewer 3 P2 we have clarified that ref 5 is the intended reference -the reference to the prepublication personal communication has been deleted. P3 HTA has been spelt out in full (Health technology Assessment) P3 Eppi-reviewer software -we have clarified that we used version 4 of the eppi-reviewer package produced by the UK EPPI-centre. We have further clarified that statistical analyses were undertaken in the METANDI package for Stata. P3 PET process: we have added the reviewer"s helpful wording to explain the additional assessment of reliability we undertook P5 reference marks are now present for all three studies P6 F18 we now present both the older and newer terms fluorodeoxyglucose/fludeoxyglucose as alternative usages with the abbreviation P18 The legend now has symbols as well as line colours for both figures Figure 1 : We"ve added some jitter and hopefully it appears a little clearer -the issue is, obviously, the true overlap of the data vs how much "error" we can introduce to give the information across! (We"ve gone for 1.5%)
